Lisa Athwal
Ophthalmology · Toms River, NJNPI 1043576630
Payments from drug & device makers
Across 296 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$681
- Johnson & Johnson Surgical Vision, Inc.$654
- AbbVie$470
- Alcon$435
- Bausch & Lomb Americas Inc.$417
- Biotissue Holdings Inc.$373
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$2044%
- Food & beverage$5,38696%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 39 | $681 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $654 |
| AbbVie(2 entities) | 32 | $470 |
| Alcon | 24 | $435 |
| Bausch & Lomb Americas Inc. | 28 | $417 |
| Biotissue Holdings Inc. | 18 | $373 |
| Kala Pharmaceuticals, Inc. | 16 | $299 |
| Oyster Point Pharma, Inc. | 16 | $259 |
| Tarsus Pharmaceuticals, Inc. | 13 | $216 |
| Dompe US, Inc. | 12 | $214 |
| Notal Vision, Inc. | 2 | $204 |
| Novartis | 15 | $192 |
| Rxsight Inc | 3 | $147 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $141 |
| Harrow Eye, LLC | 7 | $110 |
| Ocular Therapeutix, Inc. | 5 | $74 |
| Thea Pharma Inc. | 4 | $73 |
| Amgen(2 entities) | 5 | $71 |
| Mallinckrodt Hospital Products Inc. | 5 | $68 |
| Aerie Pharmaceuticals, Inc. | 4 | $58 |
| Apellis Pharmaceuticals, Inc. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $55 |
| Sight Sciences, Inc. | 3 | $38 |
| Rayner Intraocular Lenses Limited | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Eyevance Pharmaceuticals LLC | 2 | $28 |
| Eyepoint US, Inc. | 2 | $26 |
| NEW World Medical,inc. | 1 | $25 |
| Ivantis, Inc | 1 | $21 |
| Topcon Healthcare, Inc. | 1 | $21 |
| Iridex Corporation | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Beaver-visitec International, Inc. | 1 | $14 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,590 in reported general payments places this provider in the 80th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 111 | $119,055 |
| LumiganBimatoprost | 119 | $68,572 |
| XiidraLifitegrast | 26 | $37,338 |
| MieboPerfluorohexyloctane/Pf | 23 | $24,263 |
| RocklatanNetarsudil Mesylat/Latanoprost | 23 | $21,555 |
| Cyclosporine | 24 | $17,134 |
| Alphagan PBrimonidine Tartrate | 20 | $10,247 |
| Bromfenac Sodium | 71 | $10,143 |
| Brimonidine Tartrate | 83 | $7,085 |
| ProlensaBromfenac Sodium | 20 | $6,806 |
| Dexamethasone Sodium Phosphate | 142 | $6,083 |
| Latanoprost | 284 | $4,486 |
| IlevroNepafenac | 12 | $4,368 |
| Travoprost | 26 | $3,704 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $470 | $197,875250 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $417 | $61,60049 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $58 | $21,55523 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $141 | $9,49433 claims |
| NovartisIlevro | $192 | $4,36812 claims |
| AlconSimbrinza | $435 | $2,97913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Toms River
- Vipul LakhaniToms River$10K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.